- DYAX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $37.9 million.
- DYAX has traded 110,438 shares today.
- DYAX is up 3.3% today.
- DYAX was down 6.7% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in DYAX with the Ticky from Trade-Ideas. See the FREE profile for DYAX NOW at Trade-Ideas More details on DYAX: Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. Currently there are 7 analysts that rate Dyax a buy, no analysts rate it a sell, and 1 rates it a hold. The average volume for Dyax has been 1.9 million shares per day over the past 30 days. Dyax has a market cap of $3.5 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.49 and a short float of 4.2% with 5.30 days to cover. Shares are up 82.2% year-to-date as of the close of trading on Thursday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.